M. Laars et al. / Tetrahedron: Asymmetry 21 (2010) 562–565
565
135.69, 129.10, 128.60, 128.33, 128.28, 128.27, 127.24, 77.34,
77.03, 76.71, 69.06, 67.39, 66.35, 59.90, 48.33. IR: = 3063, 3031,
2857, 1739, 1496, 1455, 739, 698 cmꢂ1
Anal. Calcd for
46.67, 46.64. IR:
1122 cmꢂ1
m
= 3410, 2959, 2506, 1593, 1406, 1288,
m
.
.
C19H21NO3 (311.37): C, 73.29; H, 6.80; N, 4.50. Found: C, 73.06;
H, 6.82; N, 4.47.
4.4. General procedure for the Michael addition of propanal to
b-nitrostyrene
4.3. Preparation of morpholine carboxylic acid salts
To a solution of catalyst (0.067 mmol, 20 mol %) in appropriate
solvent (1 mL), b-nitrostyrene (50 mg, 0.34 mmol) and propanal
To a 0.05–0.09 M solution of (S)-morpholine-3-carboxylic acid
in 10:1 MeOH/H2O, 1 equiv of hydroxide was added and stirred
at rt for 2 h.
(50 lL, 0.67 mmol) were added at rt. The reaction was monitored
by TLC. After completion of the reaction, satd aq NaCl was added
and organic layer was separated. The aqueous phase was extracted
with CH2Cl2 (4 ꢀ 3 mL), dried over MgSO4, filtered, concentrated
and purified by column chromatography on silica gel (petroleum
ether/EtOAc 11:1). The ee of the product was determined by HPLC
(Chiralcel OD-H (250 ꢀ 4.6 mm) column, hexane/iPrOH 8:2, 1 mL/
min, UV 230 nm, 1 mL/min, syn: tR = 13.85 (major) and tR = 20.28
(minor). 1H NMR (400 MHz, CDCl3): 9.72 (d, J = 1.7, 1H), 7.38–
7.26 (m, 3H), 7.18–7.16 (m, 2H), 4.81 (dd, J = 5.5, 12.7, 1H), 4.69
(dd, J = 9.3, 12.7, 1H), 3.82 (td, J = 5.5, 9.2, 1H), 2.84–2.72 (m, 1H),
1.01 (d, J = 7.3, 3H).
4.3.1. (S)-Morpholine-3-carboxylic acid lithium salt
½
a 2D2
ꢁ
¼ ꢂ21:3 (c 5.8, H2O). Mp 231–233 °C. 1H NMR (400 MHz,
D2O) d 4.08–3.96 (m, 1H), 3.86–3.73 (m, 1H), 3.64–3.50 (m, 2H),
3.44–3.33 (m, 1H), 3.02–2.89 (m, 1H), 2.89–2.77 (m, 1H); 13C
NMR (101 MHz, D2O) d 178.33, 69.70, 67.37, 59.30, 44.23. IR:
m
= 3294, 2925, 2846, 1596, 1411, 1106, 1008 cmꢂ1
.
4.3.2. (S)-Morpholine-3-carboxylic acid sodium salt
½
a 2D0
ꢁ
¼ ꢂ23:9 (c 3.4, H2O). Mp 220–224 °C. 1H NMR (400 MHz,
D2O) d 3.91 (dd, J = 3.5, 11.5, 1H), 3.69 (dt, J = 3.3, 11.7, 1H),
3.54–3.40 (m, J = 4.8, 9.8, 19.6, 2H), 3.29 (dd, J = 3.5, 9.0, 1H), 2.87
(dt, J = 3.1, 13.0, 1H), 2.73 (ddd, J = 3.4, 9.8, 13.1, 1H); 13C NMR
Acknowledgements
The authors thank the Estonian Science Foundation (Grant No.
8289), the Ministry of Education and Research (Grant No.
0142725s06) and the EU European Regional Development Fund
(3.2.0101.08-0017) for financial support.
(101 MHz, D2O) d 177.12, 68.67, 66.32, 58.34, 43.29. IR:
m = 3416,
3295, 2846, 1611, 1421, 1313, 1300, 1103 cmꢂ1
.
4.3.3. (S)-Morpholine-3-carboxylic acid potassium salt
½
a 2D5
ꢁ
¼ ꢂ16:4 (c 5.3, H2O). Mp 229–233 °C. 1H NMR (400 MHz,
References
D2O) d 4.00 (dd, J = 3.5, 11.4, 1H), 3.78 (dt, J = 3.3, 11.5, 1H),
3.63–3.48 (m, 2H), 3.37 (dd, J = 3.5, 9.0, 1H), 2.99–2.91 (m, J = 3.1,
13.1, 1H), 2.82 (ddd, J = 3.3, 9.7, 13.1, 1H).; 13C NMR (101 MHz,
1. For selected reviews on organocatalysis, see: (a) Berkessel, A.; Gröger, H.
Asymmetric Organocatalysis; Wiley-VCH: Weinheim, 2005; (b) Dalko, P. I.;
Moisan, L. Angew. Chem., Int. Ed. 2004, 43, 5138–5175; (c) Seayad, J.; List, B. Org.
Biomol. Chem. 2005, 3, 719–724; (d) List, B. Chem. Commun. 2006, 819–824; (e)
Marigo, M.; Jørgensen, K. A. Chem. Commun. 2006, 2001–2011; (f) Pellissier, H.
Tetrahedron 2007, 63, 9267–9331; (g) Enders, D.; Grondal, C.; Hüttl, M. R. M.
Angew. Chem., Int. Ed. 2007, 46, 1570–1581; (h) Guillena, G.; Nájera, C.; Ramón,
D. J. Tetrahedron: Asymmetry 2007, 18, 2249–2293; (i) Gaunt, M. J.; Johansson,
C. C. C.; McNally, A.; Vo, N. T. Drug Discovery Today 2007, 12, 8–27; (j) Barbas, C.
F., III Angew. Chem., Int. Ed. 2008, 47, 42–47; (k) Dondoni, A.; Massi, A. Angew.
Chem., Int. Ed. 2008, 47, 4638–4660; (l) Bertelsen, S.; Jørgensen, K. A. Chem. Soc.
Rev. 2009, 38, 2178–2189; (m) Buckley, B. R. Annu. Rep. Prog. Chem., Sect. B: Org.
Chem. 2009, 105, 113–128.
D2O) d 180.13, 71.55, 69.21, 61.17, 46.11. IR:
m = 3343, 2961,
2851, 1587, 1452, 1411, 1303, 1106 cmꢂ1
.
4.3.4. (S)-Morpholine-3-carboxylic acid caesium salt
½
a 2D5
ꢁ
¼ ꢂ12:3 (c 5.3, H2O). Mp 217–222 °C. 1H NMR (400 MHz,
D2O) d 4.01 (dd, J = 3.5, 11.4, 1H), 3.78 (dt, J = 3.4, 11.8, 1H),
3.63–3.51 (m, 2H), 3.39 (dd, J = 3.6, 9.0, 1H), 2.97 (dt, J = 3.1, 13.1,
1H), 2.84 (ddd, J = 3.4, 9.8, 13.2, 1H). 13C NMR (101 MHz, D2O) d
2. For selected reviews on conjugate addition, see: (a) Sulzer-Mossé, S.; Alexakis,
A. Chem. Commun. 2007, 3123–3135; (b) Tsogoeva, S. B. Eur. J. Org. Chem. 2007,
1701–1716.
179.75, 71.40, 69.03, 61.09, 46.05. IR:
m = 3415, 2983, 2855, 1587,
1453, 1411, 1303, 1103 cmꢂ1
.
3. For selected examples, see: (a) Xu, Y.; Zou, W.; Sundén, H.; Ibrahem, I.; Córdova,
A. Adv. Synth. Catal. 2006, 348, 418–424; (b) Sato, A.; Yoshida, M.; Hara, S. Chem.
Commun. 2008, 6242–6244; (c) Yoshida, M.; Narita, M.; Hirama, K.; Hara, S.
Tetrahedron Lett. 2009, 50, 7297–7299; (d) Uehara, H.; Barbas, C. F., III Angew.
Chem., Int. Ed. 2009, 48, 9848–9852.
4. For selected examples, see: (a) Córdova, A.; Notz, W.; Zhong, G.; Betancort, J.
M., ; Barbas, C. F., III J. Am. Chem. Soc. 2002, 124, 1842–1843; (b) Wiesner, M.;
Upert, G.; Angelici, G.; Wennemers, H. J. Am. Chem. Soc. 2010, 132, 6–7.
5. Xu, L.-W.; Lu, Y. Org. Biomol. Chem. 2008, 6, 2047–2053.
6. (a) List, B.; Pojarliev, P.; Martin, H. J. Org. Lett. 2001, 3, 2423–2425; (b) Yu, X.;
Wang, W. Org. Biomol. Chem. 2008, 6, 2037–2046.
7. (a) Mossé, S.; Laars, M.; Kriis, K.; Kanger, T.; Alexakis, A. Org. Lett. 2006, 12,
2559–2562; (b) Laars, M.; Ausmees, K.; Uudsemaa, M.; Tamm, T.; Kanger, T.;
Lopp, M. J. Org. Chem. 2009, 74, 3772–3775.
8. Kogami, Y.; Okawa, K. Bull. Chem. Soc. Jpn. 1987, 60, 2963–2965.
9. Synthesis of Fmoc-protected morpholine 3-carboxylic acid see: Sladojevich, F.;
Trobacchi, A.; Guarna, A. J. Org. Chem. 2007, 72, 4254–4257.
10. Brown, G. R.; Foubister, A. J.; Wright, B. J. Chem. Soc., Perkin Trans. 1 1985, 2577–
2580.
11. Yamaguchi, M.; Shiraishi, T.; Hirama, M. J. Org. Chem. 1996, 61, 3520–
3530.
12. Seebach, D.; Golinski, J. Helv. Chim. Acta 1981, 64, 1413–1423.
4.3.5. (S)-Morpholine-3-carboxylic acid tetrabutyl ammonium
salt
½
a 2D0
ꢁ
¼ ꢂ15:0 (c 1, H2O). 1H NMR (400 MHz, D2O) d 3.99 (dd,
J = 3.5, 11.4, 1H), 3.77 (dt, J = 3.4, 11.7, 1H), 3.59–3.49 (m, 2H),
3.36 (dd, J = 3.5, 9.0, 1H), 3.24–3.12 (m, 8 H), 2.94 (dt, J = 3.1,
13.3, 1H), 2.81 (ddd, J = 3.3, 9.7, 13.1, 1H), 1.69–1.58 (m, 8H),
1.42–1.27 (m, 8H), 0.94 (t, J = 7.3, 12H); 13C NMR (101 MHz,
D2O) d 180.09, 71.55, 69.21, 61.17, 60.83, 60.80, 60.78, 46.10,
25.82, 21.84, 15.52. IR: 3348, 2961, 2876, 1600, 1489, 1383,
1304, 1228, 1102 cmꢂ1
.
4.3.6. (S)-Piperazine-2-carboxylic acid sodium salt
½
a 2D0
ꢁ
¼ ꢂ6:4 (c 1.7, H2O). Mp 233–238 °C. 1H NMR (400 MHz,
D2O) d 3.21 (dd, J = 3.2, 10.1, 1H), 3.10 (dd, J = 2.9, 12.6, 1H),
2.98–2.87 (m, 1H), 2.86–2.76 (m, 1H), 2.74–2.64 (m, 1H), 2.63–
2.52 (m, 2H); 13C NMR (101 MHz, D2O) d 181.48, 61.90, 50.25,